A new study led by Cleveland Clinic researchers suggests that the small molecule ONC201 has promise as a less toxic treatment for pheohromocytomas/paragangliomas, and possibly other rare neuroendocrine tumors as well.
Results of a Phase 2 trial offer much-needed guidance to clinicians treating a rare and aggressive form of sarcoma. Dr. Peter Anderson explains.
With greater precision made possible through image guidance, radiotherapy combined with new chemotherapeutics means radiation will be desirable instead of feared in childhood cancer therapy.
This noted pediatric osteosarcoma expert shares his proudest discovery and a few reflections on patient care as he settles in at Cleveland Clinic Children’s.